← Back to Search

Behavioural Intervention

Smoking Cessation for People Living With HIV/AIDS

N/A
Waitlist Available
Led By David Ledgerwood, PhD
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline: weekly through treatment phase 1; between 0 to 16 times during treatment phase 2 (non-responders meet 16 times; responders meet 0 or 6 times depending on group)
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

This trial will help researchers understand how to better help people with HIV/AIDS quit smoking.

Eligible Conditions
  • HIV/AIDS
  • Smoking Addiction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline: weekly in treatment phase 1; between 0 to 16 times during treatment phase 2 (non-responders meet 16 times; responders meet 0 or 6 times depending on group); follow-up interviews (post-phase 1, post-phase 2, 6-months and 12-months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline: weekly in treatment phase 1; between 0 to 16 times during treatment phase 2 (non-responders meet 16 times; responders meet 0 or 6 times depending on group); follow-up interviews (post-phase 1, post-phase 2, 6-months and 12-months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Carbon Monoxide Results
Longest Duration of Continuous Abstinence
Seven-Day Point-Prevalence
+1 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Phase 2b: Responders (B)Experimental Treatment3 Interventions
Bupropion, continued monitoring and low intensity prize contingency management.
Group II: Phase 2b: Responders (A)Experimental Treatment2 Interventions
Bupropion, no additional treatment.
Group III: Phase 2a: Non-Responders (B)Experimental Treatment3 Interventions
Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
Group IV: Phase 2a Non-Responders (A)Experimental Treatment3 Interventions
Bupropion, continued counseling, monitored support to quit smoking.
Group V: Phase 1: Standard of Care (B)Experimental Treatment3 Interventions
Brief counseling, bupropion, and brief high-magnitude prize contingency management.
Group VI: Phase 1: Standard of Care (A)Experimental Treatment2 Interventions
Brief counseling and bupropion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupropion
FDA approved
Brief Counseling
2021
N/A
~1230
No additional treatment
2006
N/A
~50

Find a Location

Who is running the clinical trial?

Wayne State UniversityLead Sponsor
315 Previous Clinical Trials
110,772 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,607 Previous Clinical Trials
3,329,650 Total Patients Enrolled
David Ledgerwood, PhDPrincipal InvestigatorWayne State University
1 Previous Clinical Trials
150 Total Patients Enrolled
~13 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top